Fig. 1: In vivo therapeutic efficacy of unlabeled antibodies and of ¹⁷⁷Lu-lilotomab.

a The number of CD37 receptors per cell was determined in all the cell lines by Scatchard analysis (n = 3) [26]. b SCID mice bearing DOHH2 cell xenografts received one intravenous injection of ¹⁷⁷Lu-lilotomab (100 MBq/kg, 0.5 mg/kg), nonspecific ¹⁷⁷Lu-cetuximab (125 MBq/kg, 0.6 mg/kg), or unlabeled mAbs (0.5 mg/kg) (n = 6–8/group). Tumor growth (left panel) was plotted as a function of time post xenograft, and Kaplan–Meyer survival curves were established (right panel). c Athymic mice bearing Ramos cell xenografts received one intravenous injection of ¹⁷⁷Lu-lilotomab at 250 MBq/kg or 500 MBq/kg, ¹⁷⁷Lu-cetuximab at 400 MBq/kg, or unlabeled mAbs (2.5 mg/kg) (n = 6–9/group). Tumor growth (left panel) was monitored as a function of time post xenograft, and Kaplan–Meyer survival curves were established (right panel); *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 (compared with the NaCl-treated group).